The Pharma Data

JANUARY 13, 2021

We are humbled by the expeditious review of our supplemental new drug application and hope our broad development program for tislelizumab will continue its momentum and benefit additional patients,” said Wendy Yan, Senior Vice President and Global Head of Regulatory Affairs at BeiGene. ii She J, Yang P, Hong Q, et al.

Production 52

Production Trials Antibody Clinical Trials 52

The Pharma Data

DECEMBER 27, 2020

We are appreciative of our team’s efforts and our collaboration with Amgen in developing and commercializing these medicines, and understand that this accomplishment would not have been possible without China’s commitment to innovative, high-quality treatments through ongoing drug reform and the Healthy China initiative.”. .

Production 52

Production Drugs Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 14, 2020

For example, the S&P 500 is just 100 points below its pre-pandemic peak while NASDAQ had fully recovered its losses by early June and is now reporting record highs. percent of applicants have apparently been defrauding the program by “double-dipping”, a no-no that the federal government is threatening to punish. billion in June.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92